Skip to main content

Table 1 Association of baseline characteristics with ICTOS in both training and validation sets

From: Development and validation of a novel MR imaging predictor of response to induction chemotherapy in locoregionally advanced nasopharyngeal cancer: a randomized controlled trial substudy (NCT01245959)

  Training set  
  Low ICTOS (n = 138) High ICTOS (n = 116) P value Low ICTOS (n = 175) High ICTOS (n = 73) P value
Age    0.06 0.49   0.49
 < 42 years 45 (32.6) 52 (44.8)   81 (46.3) 38 (52.1)  
 ≥ 42 years 93 (67.4) 64 (55.2)   94 (53.7) 35 (47.9)  
Sex    0.02    0.40
 Male 109 (79.0) 75 (64.7)   144 (82.3) 56 (76.7)  
 Female 29 (21.0) 41 (35.3)   31 (17.7) 17 (23.3)  
Staginga    0.04    0.80
 III 84 (70.9) 55 (47.4)   95 (65.7) 46 (73.0)  
 IV 54 (39.1) 61 (52.6)   60 (34.3) 27 (37.0)  
T stagea    0.21    0.33
 T1 4 (2.9) 2 (1.7)   5 (2.9) 1 (1.4)  
 T2 14 (10.1) 7 (6.0)   8 (4.6) 5 (6.8)  
 T3 82 (59.4) 62 (53.4)   114 (65.1) 40 (54.8)  
 T4 38 (27.5) 45 (38.8)   48 (27.4) 27 (37.0)  
N stagea    0.48 0.08   0.08
 N1 66 (47.8) 47 (40.5)   98 (56.0) 36 (49.3)  
 N2 50 (36.2) 46 (39.7)   62 (35.4) 35 (47.9)  
 N3 22 (15.9) 23 (19.8)   15 (8.6) 2 (2.7)  
Cervical nodal necrosis    0.90    0.32
 No 99 (71.7) 85 (73.3)   114 (65.1) 53 (72.6)  
 Yes 39 (28.3) 31 (26.7)   61 (34.9) 20 (27.4)  
Primary tumor volume < 0.001   < 0.001 0.56   0.56
 < 34 ml 97 (70.3) 53 (45.7)   88 (50.3) 33 (45.2)  
 ≥ 34 ml 41 (29.7) 63 (54.3)   87 (49.7) 40 (54.8)  
Pretreatment pEBV DNA level    0.17    0.08
 < 2000 copy/ml 75 (54.3) 52 (44.8)   60 (45.7) 24 (32.9)  
 ≥ 2000 copy/ml 63 (45.7) 64 (55.2)   95 (54.3) 49 (67.1)  
Chemoradiotherapy regimen    0.22    0.64
 ICT+CCRT 62 (44.9) 62 (53.4)   86 (49.1) 39 (53.4)  
 CCRT 76 (55.1) 54 (46.6)   89 (50.9) 34 (46.6)  
  1. ICTOS Induction Chemotherapy Outcomes Score, pEBV DNA plasma Epstein–Barr Virus DNA, CCRT concurrent chemoradiotherapy, ICT, induction chemotherapy
  2. aStaging, T classification, and N classification were based on the 7th edition of the American Joint Committee on Cancer/International Union Against Cancer staging systems
\